Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: A review

Therapeutic Delivery

Volumn 1, Issue 5, 2010, Pages 713-734

  Bhattacharjee, Himanshu ^a   Balabathula, Pavan ^a   Wood, George C ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CAMPTOTHECIN; CARBON NANOTUBE; DACARBAZINE; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FULLERENE; IMMUNOLIPOSOME; MIGLYOL; MYRITOL; NANOPARTICLE; POLYAMIDOAMINE; POLYAMINE; POLYPEPTIDE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG RETENTION; DRUG SOLUBILITY; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; LIPOSOMAL DELIVERY; MACROMOLECULE; MELANOMA; MICELLE; NANOEMULSION; NANOENCAPSULATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; RETICULOENDOTHELIAL SYSTEM; REVIEW; SOLID TUMOR; TUMOR GROWTH;

EID: 79954558676     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.47     Document Type: Review

References (133)

1. Zhang D, Feng XY, Henning TD, et al. Mr imaging of tumor angiogenesis using sterically stabilized gd-dtpa liposomes targeted to cd105. Eur. J. Radiol. 70(1), 180-189 (2009). n Discusses the current status of the emerging field of theragnostics, as well as the future prospect of these novel agents in drug delivery.
2. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J. Obstet. Gynecol. 48(3), 239-244 (2009).
3. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010).
4. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86(3), 215-223 (2009).
5. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26(1), 57-642008).
6. Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 128(3), 185-199 (2008).
7. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120(12), 2527-2537 (2007). (Pubitemid 46651272)
8. Fawaz F, Bonini F, Guyot M, Lagueny AM, Fessi H, Devissaguet JP. Influence of poly(dl-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharmacol. Res. 10(5), 750-756 (1993). (Pubitemid 23152324)
9. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010).
10. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006). (Pubitemid 41773257)
11. Rippe B, Rosengren BI, Carlsson O, Venturoli D. Transendothelial transport: the vesicle controversy. J. Vasc. Res. 39(5), 375-390 (2002).
12. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS (96), 223-268 (2006).
13. Feng D, Nagy JA, Dvorak HF, Dvorak AM. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc. Res. Tech. 57(5), 289-326 (2002). (Pubitemid 34579214)
14. Hume DA. The mononuclear phagocyte system. Curr. Opin. Immunol. 18(1), 49-53 (2006). (Pubitemid 43049647)
15. Nakayama H, Enzan H, Miyazaki E, et al. Lack of vascular adventitial fibroblastic cells in tumor stroma of intestinal-type and solid-type gastric carcinomas. J. Clin. Pathol. 57(2), 183-185 (2004). (Pubitemid 38177759)
16. Ashraf S, Loizidou M, Crowe R, Turmaine M, Taylor I, Burnstock G. Blood vessels in liver metastases from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells. Clin. Exp. Metastasis 15(5), 484-498 (1997). (Pubitemid 27323898)
17. Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit. Care Med. 37(Suppl. 1), S50-58 (2009).
18. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti-tumor agent smancs. Cancer Res. 46, 6387-6392 (1986). (Pubitemid 17221789)
19. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409-419 (2009).
20. Saini V, Shoemaker RH. Potential for therapeutic targeting of tumor stem cells. Cancer Sci. 101(1), 16-21 (2010).
21. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J. Clin. Oncol. 27(29), 4834-4838 (2009).
22. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res. 69(4), 1259-1262 (2009).
23. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241-263 (1999). (Pubitemid 129740012)
24. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004). (Pubitemid 39331152)
25. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998). (Pubitemid 28063372)
26. Hirai M, Hiramatsu Y, Iwashita S, et al. E-selectin targeting to visualize tumors in vivo. Contrast Media Mol. Imaging 5(2), 70-77 (2010).
27. Nallamothu R, Wood GC, Kiani MF, Moore BM, Horton FP, Thoma LA. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. PDA J. Pharm. Sci. Technol. 60(3), 144-155 (2006). (Pubitemid 43974711)
28. Nallamothu R, Wood GC, Pattillo CB, et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. AAPS PharmSciTech 7(2), E32 (2006).
29. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
30. Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. RGD-based strategies for improving anti-tumor activity of paclitaxelloaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug Target. 17(1), 10-18 (2009).
31. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163(4), 871-878 (2003). (Pubitemid 37517893)
32. Christian S, Ahorn H, Koehler A, et al. Molecular cloning and characterization of endosialin, a c-type lectin-like cell surface receptor of tumor endothelium. J. Biol. Chem. 276(10), 7408-7414 (2001).
33. Henke E, Perk J, Vider J, et al. Peptideconjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat. Biotechnol. 26(1), 91-100 (2008).
34. Drecoll E, Gaertner FC, Miederer M, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 4(5), e5715 (2009).
35. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. (Maywood) 234(2), 123-131 (2009).
36. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond.) 5(3), 485-505 (2010).
37. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48(2), 101-111 (1999). (Pubitemid 29401986)
38. Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG-PLA/pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 31(8), 2371-2379 (2010).
39. Cai S, Vijayan K, Cheng D, Lima EM, Discher DE. Micelles of different morphologies - advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm. Res. 24(11), 2099-2109 (2007). (Pubitemid 47493571)
40. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcuminencapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.) 5(3), 433-449 (2010).
41. Kim JO, Sahay G, Kabanov AV, Bronich TK. Polymeric micelles with ionic cores containing biodegradable cross-links for delivery of chemotherapeutic agents. Biomacromolecules 11(4 919-926 (2010).
42. Richter A, Olbrich C, Krause M, Hoffmann J, Kissel T. Polymeric micelles for parenteral delivery of sagopilone: physicochemical characterization, novel formulation approaches and their toxicity assessment in vitro as well as in vivo. Eur. J. Pharm. Biopharm. 75(2), 80-89 (2010).
43. Sawant RM, Hurley JP, Salmaso S, et al. 'Smart' drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17(4), 943-9492006). (Pubitemid 44162612)
44. Nasongkla N, Shuai X, Ai H, et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem. Int. Ed. Engl. 43(46), 6323-6327 (2004). (Pubitemid 40029462)
45. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev. 61(10 768-784 (2009).
46. Oh KT, Oh YT, Oh NM, Kim K, Lee DH, Lee ES. A smart flower-like polymeric micelle for pH-triggered anticancer drug release. Int. J. Pharm. 375(1-2), 163-1692009).
47. Jiang X, Liu S, Narain R. Degradable thermoresponsive core cross-linked micelles: fabrication, surface functionalization, and biorecognition. Langmuir 25(23 13344-13350 (2009).
48. Skidan I, Dholakia P, Torchilin V. Photodynamic therapy of experimental b-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J. Drug Target. 16(6), 486-4932008). (Pubitemid 352015817)
49. Liu H, Zhu Z, Kang H, Wu Y, Sefan K, Tan W. DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. Chemistry 16(12), 3791-3797 (2010).
50. Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin b. Drugs Today (Barc.) 40(2), 133-145 (2004). (Pubitemid 38387618)
51. Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. 31(6) (Suppl. 13), 5-15 (2004). (Pubitemid 40023239)
52. Seale-Goldsmith MM, Leary JF. Nanobiosystems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(5), 553-567 (2009).
53. Chandran S, Roy A, Mishra B. Recent trends in drug delivery systems: liposomal drug delivery system - preparation and characterization. Indian J. Exp. Biol. 35(8), 801-809 (1997). (Pubitemid 127482956)
54. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 10(4), 711-719 (2005). (Pubitemid 43161695)
55. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30(11), 592-599 (2009).
56. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51(4), 691-743 (1999).
57. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1(3), 297-315 (2006).
58. Ogawara K, Un K, Tanaka K, Higaki K, Kimura T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOXresistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J. Control. Release 133(1), 4-10 (2009).
59. Bruckheimer E, Harvie P, Orthel J, et al. In vivo efficacy of folate-targeted lipidprotamine- DNA (LPD-PEG-folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma. Cancer Gene Ther. 11(2), 128-134 (2004). (Pubitemid 38141775)
60. Hu Y, Li K, Wang L, Yin S, Zhang Z, Zhang Y. Pegylated immuno-lipopolyplexes: a novel nonviral gene delivery system for liver cancer therapy. J. Control. Release 144(1), 75-81 (2010).
61. Tomalia DA. Dendrimer research. Science 252(5010), 1231 (1991).
62. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine (Lond.) 3(5), 679-702 (2008).
63. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6(8), 427-436 (2001). (Pubitemid 32328297)
64. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J. Intern. Med. 267(1), 9-21 (2010).
65. Hwang SH, Moorefield C, Newkome G. Dendrimers in the spotlight. Phys. Chem. Chem. Phys. 10(42), T87 (2008).
66. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 15(5-6), 171-185 (2010).
67. Coles DJ, Toth I. Dendritic peptide-based carriers for gene delivery. Curr. Drug Deliv. 6(4), 338-342 (2009).
68. Baker JR Jr. Dendrimer-based nanoparticles for cancer therapy. Hematology Am. Soc. Hematol. Educ. Program 708-719 (2009).
69. Nishiyama N, Morimoto Y, Jang WD, Kataoka K. Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv. Drug Deliv. Rev. 61(4), 327-338 (2009).
70. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat. Biotechnol. 23(12), 1517-1526 (2005). (Pubitemid 41752929)
71. Jiang YY, Tang GT, Zhang LH, Kong SY, Zhu SJ, Pei YY. Pegylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J. Drug Target. 18(5), 389-403 (2010).
72. Sousa AA, Aronova MA, Wu H, Sarin H, Griffiths GL, Leapman RD. Determining molecular mass distributions and compositions of functionalized dendrimer nanoparticles. Nanomedicine (Lond.) 4(4 391-399 (2009).
73. Al-Jamal KT, Al-Jamal WT, Akerman S, et al. Systemic antiangiogenic activity of cationic poly-l-lysine dendrimer delays tumor growth. Proc. Natl Acad. Sci. USA 107(9), 3966-3971 (2010).
74. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug. Chem. 20(10), 1908-1916 (2009).
75. Koppu S, Oh YJ, Edrada-Ebel R, et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control. Release 143(2), 215-221 (2010).
76. Majoros IJ, Williams CR, Becker A, Baker JR Jr. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(5), 502-510 (2009).
77. Wiener EC, Pamidighantam B, Narayanan VV. A nanotechnology-based analog of monoclonal antibodies for targeted delivery of diagnostic and therapeutic agents. Conf. Proc. IEEE. Eng. Med. Biol. Soc. 7, 5242-5245 (2004). (Pubitemid 40035039)
78. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 10(1), 35-43 (2005). (Pubitemid 40164817)
79. Rupp R, Rosenthal SL, Stanberry LR. Vivagel (SPL7013 gel): a candidate dendrimer - microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2(4), 561-566 (2007).
80. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem. Rev. 109(1), 49-87 (2009).
81. Rasines B, Hernandez-Ros JM, de las Cuevas N, et al. Water-stable ammonium-terminated carbosilane dendrimers as efficient antibacterial agents. Dalton Trans. (40), 8704-8713 (2009).
82. Santos JL, Oliveira H, Pandita D, et al. Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J. Control. Release 144(1), 55-64 (2010).
83. Ooya T, Lee J, Park K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J. Control. Release 93(2), 121-127 (2003).
84. Bhadra D, Bhadra S, Jain S, Jain NK. A pegylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257(1-2), 111-124 (2003). (Pubitemid 36507038)
85. Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y. PEGylated PAMAM dendrimerdoxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm. Res. 27(1), 161-174 (2010).
86. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem. 19(11), 2239-2252 (2008).
87. Lim J, Chouai A, Lo ST, Liu W, Sun X, Simanek EE. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages. Bioconjug. Chem. 20(11), 2154-2161 (2009).
88. Santos JL, Pandita D, Rodrigues J, et al. Receptor-mediated gene delivery using pamam dendrimers conjugated with peptides recognized by mesenchymal stem cells. Mol. Pharm. 7(3), 763-774 (2010).
89. Ofek P, Fischer W, Calderon M, Haag R, Satchi-Fainaro R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. Faseb. J. 24, 3122-3134 (2010).
90. Tziveleka LA, Psarra AM, Tsiourvas D, Paleos CM. Synthesis and evaluation of functional hyperbranched polyether polyols as prospected gene carriers. Int. J. Pharm. 356(1-2), 314-324 (2008).
91. Takino T, Nakajima C, Takakura Y, Sezaki H, Hashida M. Controlled biodistribution of highly lipophilic drugs with various parenteral formulations. J. Drug Target. 1(2), 117-124 (1993).
92. Tagne JB, Kakumanu S, Nicolosi RJ. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol. Pharm. 5(6), 1055-1063(2008).
93. Tagne JB, Kakumanu S, Ortiz D, Shea T, Nicolosi RJ. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol. Pharm. 5(2), 280-286 (2008). (Pubitemid 351579131)
94. Han M, He CX, Fang QL, et al. A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo. Pharm. Res. 26(4), 926-935 (2009).
95. Ohguchi Y, Kawano K, Hattori Y, Maitani Y. Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: Effect of chain length and amount of folate-PEG linker. J. Drug Target. 16(9), 660-667 (2008).
96. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71(2), 161-172 (2009).
97. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Nonstealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv. administration to rats. Pharmacol. Res. 42(4), 337-343 (2000).
98. Scholer N, Olbrich C, Tabatt K, Muller RH, Hahn H, Liesenfeld O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm. 221(1-2), 57-67 (2001). (Pubitemid 32524035)
99. Scholer N, Hahn H, Muller RH, Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 231(2), 167-176 (2002). (Pubitemid 34033676)
100. Shenoy VS, Vijay IK, Murthy RS. Tumor targeting: biological factors and formulation advances in injectable lipid nanoparticles. J. Pharm. Pharmacol. 57(4), 411-422 (2005).
101. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59(6), 491-504 (2007). (Pubitemid 47259227)
102. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. (Tokyo) 49(11), 1444-1447 (2001). (Pubitemid 33043274)
103. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59(3), 299-307 (1999). (Pubitemid 29238174)
104. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of nonstealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 10(4), 327-335 (2002). (Pubitemid 34746314)
105. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Release 95(3), 613-626 (2004). (Pubitemid 38340510)
106. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumor targeting. J. Microencapsul. 25(5), 289-297 (2008). (Pubitemid 352025005)
107. Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm. Res. 27(8), 1584-1596 (2010).
108. Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J. Drug Target.17(10), 777-787 (2009).
109. Poirier DM, Ohno TR, Kroll GH, et al. Formation of fullerides and fullerene-based heterostructures. Science 253(5020), 646-648 (1991). (Pubitemid 21917194)
110. Jensen AW, Wilson SR, Schuster DI. Biological applications of fullerenes. Bioorg. Med. Chem. 4(6), 767-779 (1996). (Pubitemid 26202375)
111. Djordjevic A, Bogdanovic G, Dobric S. Fullerenes in biomedicine. J. BUON 11(4), 391-404 (2006). (Pubitemid 46729851)
112. Zhu E, Liu R, Lv M, et al. Preparation and characterization of a new hydrophilic C60 derivative (OH)16C60CHCOOH. J. Nanosci. Nanotechnol. 10(2), 927-932 (2010).
113. Ashcroft JM, Tsyboulski DA, Hartman KB, et al. Fullerene (C60) immunoconjugates. Interaction of watersoluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem. Commun. (Camb.) (28), 3004-3006 (2006). (Pubitemid 44036435)
114. Jin C, Suenaga K, Iijima S. Plumbing carbon nanotubes. Nat. Nanotechnol. 3(1), 17-21 (2008).
115. Yang ST, Wang H, Meziani MJ, Liu Y, Wang X, Sun YP. Biodefunctionalization of functionalized single-walled carbon nanotubes in mice. Biomacromolecules 10(7), 2009-2012 (2009).
116. Zhang D, Deng X, Ji Z, et al. Long-term hepatotoxicity of polyethylene-glycol functionalized multiwalled carbon nanotubes in mice. Nanotechnology 21(17), 175101 (2010).
117. Prencipe G, Tabakman SM, Welsher K, et al. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. J. Am. Chem. Soc. 131(13), 4783-4787 (2009).
118. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumor targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2(1), 47-52 (2007). (Pubitemid 46210038)
119. Welsher K, Liu Z, Daranciang D, Dai H. Selective probing and imaging of cells with single walled carbon nanotubes as nearinfrared fluorescent molecules. Nano. Lett. 8(2), 586-590 (2008). (Pubitemid 351346022)
120. Bhirde AA, Patel V, Gavard J, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3(2), 307-316 (2009).
121. Wu W, Li R, Bian X, et al. Covalently combining carbon nanotubes with anticancer agent: preparation and anti-tumor activity. ACS Nano 3(9), 2740-2750 (2009).
122. Zhang X, Meng L, Lu Q, Fei Z, Dyson PJ. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 30(30), 6041-6047 (2009).
123. Marches R, Chakravarty P, Musselman IH, et al. Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies. Int. J. Cancer 125(12), 2970-2977 (2009).
124. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005). (Pubitemid 41112931)
125. Al-Jamal KT, Sakthivel T, Florence AT. Dendrisomes: cationic lipidic dendron vesicular assemblies. Int. J. Pharm. 254(1), 33-36 (2003). (Pubitemid 36259806)
126. Al-Jamal KT, Sakthivel T, Florence AT. Dendrisomes: vesicular structures derived from a cationic lipidic dendron. J. Pharm. Sci. 94(1), 102-113 (2005). (Pubitemid 40116374)
127. Dutta T, Burgess M, McMillan NA, Parekh HS. Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine (Lond.) 6(3), 463-470 (2010).
128. Zakharian TY, Seryshev A, Sitharaman B, Gilbert BE, Knight V, Wilson LJ. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J. Am. Chem. Soc. 127(36), 12508-12509 (2005). (Pubitemid 41292167)
129. You J, Zhang G, Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 4(2), 1033-1041 (2010).
130. Gaharwar AK, Wong JE, Muller-Schulte D, Bahadur D, Richtering W. Magnetic nanoparticles encapsulated within a thermoresponsive polymer. J. Nanosci. Nanotechnol. 9(9), 5355-5361 (2009).
131. Gao Z, Kennedy AM, Christensen DA, Rapoport NY. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics 48(4), 260-270 (2008).
132. American Cancer Society. Cancer Facts and Figures 2009. (2009).
133. Bouchemal K, Briancon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int. J. Pharm. 280(1-2), 241-251 (2004). (Pubitemid 38960674)